Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Cytotoxic Drugs Market: By Product Type, By Route of Administration, By Application, By End User, and Geography
Cytotoxic Drugs Market: By Product Type, By Route of Administration, By Application, By End User, and Geography
Cytotoxic Drugs Market size was valued at US$ 14.6 billion in 2023 and is poised to grow at a significant CAGR of 5.6% from 2024-2030. Cytotoxic drugs, also known as antineoplastics, are a group of medicines that contain toxic chemicals to cells, preventing their replication or growth. They are widely used to treat various cancers and other disorders, such as rheumatoid arthritis and multiple sclerosis. Cytotoxic drugs can destroy tumors and reduce metastases and lessen cancer symptoms. Cancer cells replicate faster than normal cells, making them susceptible to cytostatics. The effects on normal cells are less pronounced, and healthy cells recover faster.
According to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The most common cancer in 2020 was breast cancer (2.26 million cases), lung (2.21 million cases), etc. Moreover, increasing use and approval of cytotoxic drugs are also expected to boost the market growth. Also, the growing therapeutic area of cytotoxic drugs in auto-immune conditions such as rheumatoid arthritis, psoriasis, or prevention of transplant rejection is influencing the overall cytotoxic market growth.
However, the adverse side effects of the consumption of cytotoxic drugs, such as nausea and vomiting, severe diarrhea, and damage to normal cells and tissue, are restraining the market growth. Based on the product type, the global cytotoxic market is segmented into alkylating agents, antitumor antibiotics, antimetabolites, plant alkaloids, and others. The antimetabolites segment held the major market revenue in 2021.
Study Period
2024-2030Base Year
2023CAGR
5.6%Largest Market
Asia PacificFastest Growing Market
North America
The surging number of cancer patients worldwide boosts the global cytotoxic market growth. It is mainly attributed to the increasing number of cigarette smokers and secondary smoke exposure, exposure to sun and tanning beds, overweight and obesity, excessive alcohol use, and various infectious disease. According to the National Cancer Institute, around 1,806,590 new cancer cases are diagnosed in the United States. Therefore, the adoption of cytotoxic chemotherapy drugs is expected to boost the global cytotoxic drugs market growth at a significant rate.
The market share is divided into North America, Asia-pacific, Europe, the Middle East, and the African region. The cytotoxic drugs market in the Asia Pacific is likely to hold a significant revenue share in 2022. In the following years, it is predicted to increase rapidly due to the increasing number of cancer patients in this region. North America dominates the market due to innovative product developments, the high adoption rate of new therapies, and major market players in this region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 14.6 billion |
|
Market CAGR |
5.6% |
|
By Product Type |
|
|
By Application |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
The global cytotoxic drugs market size was valued at US$ 14.6 billion in 2023 and is projected to grow at a CAGR of 5.6% from 2024-2030.
The leading players in the global cytotoxic drugs market are Pfizer Inc., AbbVie Inc., Johnson & Johnson, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, Merck & Co. Inc., Sanofi, Novartis AG, Eli Lilly and Company, and Amgen.
North America is dominating the global cytotoxic drugs market.
The fastest-growing segment of the global cytotoxic drugs market is antimetabolite drugs.
| 1. Executive Summary |
| 2. Global Cytotoxic Drug Market Introduction |
| 2.1. Global Cytotoxic Drug Market Taxonomy |
| 2.2. Global Cytotoxic Drug Market Definitions |
| 2.2.1. By Product Type |
| 2.2.2. By Route of Administration |
| 2.2.3. By Application |
| 2.2.4. By End User |
| 2.2.5. By Region |
| 3. Global Cytotoxic Drug Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Cytotoxic Drug Market Dynamic Factors - Impact Analysis |
| 3.6. Global Cytotoxic Drug Market Competition Landscape |
| 3.7. Epidemiology |
| 4. Global Cytotoxic Drug Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Cytotoxic Drug Market, By Product Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Alkylating Agents |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Antitumor Antibiotics |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Antimetabolites |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Plant Alkaloids |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Cytotoxic Drug Market, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Parental |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Cytotoxic Drug Market, By Application, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. Breast Cancer |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Prostate Cancer |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Lung Cancer |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Pancreatic Cancer |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. Global Cytotoxic Drug Market, By End User, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. Retail Pharmacy |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Hospital Pharmacy |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacy |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9. Global Cytotoxic Drug Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 9.6. Global Cytotoxic Drug Market - Opportunity Analysis Index, By Product Type, By Route of Administration, By Application, By End User, and Region, 2024 - 2030 |
| 10. North America Cytotoxic Drug Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Alkylating Agents |
| 10.1.2. Antitumor Antibiotics |
| 10.1.3. Antimetabolites |
| 10.1.4. Plant Alkaloids |
| 10.1.5. Others |
| 10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Oral |
| 10.2.2. Parental |
| 10.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Breast Cancer |
| 10.3.2. Prostate Cancer |
| 10.3.3. Lung Cancer |
| 10.3.4. Pancreatic Cancer |
| 10.3.5. Others |
| 10.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Retail Pharmacy |
| 10.4.2. Hospital Pharmacy |
| 10.4.3. Online Pharmacy |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.5.1. USA |
| 10.5.2. Canada |
| 10.6. North America Cytotoxic Drug Market - Opportunity Analysis Index, By Product Type, By Route of Administration, By Application, By End User, and Country, 2024 - 2030 |
| 10.7. North America Cytotoxic Drug Market Dynamics Trends |
| 11. Europe Cytotoxic Drug Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Alkylating Agents |
| 11.1.2. Antitumor Antibiotics |
| 11.1.3. Antimetabolites |
| 11.1.4. Plant Alkaloids |
| 11.1.5. Others |
| 11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Oral |
| 11.2.2. Parental |
| 11.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Breast Cancer |
| 11.3.2. Prostate Cancer |
| 11.3.3. Lung Cancer |
| 11.3.4. Pancreatic Cancer |
| 11.3.5. Others |
| 11.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Retail Pharmacy |
| 11.4.2. Hospital Pharmacy |
| 11.4.3. Online Pharmacy |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. Germany |
| 11.5.2. UK |
| 11.5.3. France |
| 11.5.4. Spain |
| 11.5.5. Italy |
| 11.5.6. Rest of Europe |
| 11.6. Europe Cytotoxic Drug Market - Opportunity Analysis Index, By Product Type, By Route of Administration, By Application, By End User, and Country, 2024 - 2030 |
| 11.7. Europe Cytotoxic Drug Market Dynamics Trends |
| 12. Asia-Pacific Cytotoxic Drug Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Alkylating Agents |
| 12.1.2. Antitumor Antibiotics |
| 12.1.3. Antimetabolites |
| 12.1.4. Plant Alkaloids |
| 12.1.5. Others |
| 12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Oral |
| 12.2.2. Parental |
| 12.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Breast Cancer |
| 12.3.2. Prostate Cancer |
| 12.3.3. Lung Cancer |
| 12.3.4. Pancreatic Cancer |
| 12.3.5. Others |
| 12.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Retail Pharmacy |
| 12.4.2. Hospital Pharmacy |
| 12.4.3. Online Pharmacy |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. China |
| 12.5.2. India |
| 12.5.3. Japan |
| 12.5.4. ASEAN |
| 12.5.5. Australia & New Zealand |
| 12.5.6. Rest of Asia-Pacific |
| 12.6. Asia-Pacific Cytotoxic Drug Market - Opportunity Analysis Index, By Product Type, By Route of Administration, By Application, By End User, and Country, 2024 - 2030 |
| 12.7. Asia-Pacific Cytotoxic Drug Market Dynamics Trends |
| 13. Latin America Cytotoxic Drug Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 13.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Alkylating Agents |
| 13.1.2. Antitumor Antibiotics |
| 13.1.3. Antimetabolites |
| 13.1.4. Plant Alkaloids |
| 13.1.5. Others |
| 13.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Oral |
| 13.2.2. Parental |
| 13.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Breast Cancer |
| 13.3.2. Prostate Cancer |
| 13.3.3. Lung Cancer |
| 13.3.4. Pancreatic Cancer |
| 13.3.5. Others |
| 13.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Retail Pharmacy |
| 13.4.2. Hospital Pharmacy |
| 13.4.3. Online Pharmacy |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Brazil |
| 13.5.2. Mexico |
| 13.5.3. Rest of Latin America |
| 13.6. Latin America Cytotoxic Drug Market - Opportunity Analysis Index, By Product Type, By Route of Administration, By Application, By End User, and Country, 2024 - 2030 |
| 13.7. Latin America Cytotoxic Drug Market Dynamics Trends |
| 14. Middle East and Africa Cytotoxic Drug Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 14.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1. Alkylating Agents |
| 14.1.2. Antitumor Antibiotics |
| 14.1.3. Antimetabolites |
| 14.1.4. Plant Alkaloids |
| 14.1.5. Others |
| 14.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1. Oral |
| 14.2.2. Parental |
| 14.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Breast Cancer |
| 14.3.2. Prostate Cancer |
| 14.3.3. Lung Cancer |
| 14.3.4. Pancreatic Cancer |
| 14.3.5. Others |
| 14.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Retail Pharmacy |
| 14.4.2. Hospital Pharmacy |
| 14.4.3. Online Pharmacy |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Gulf Cooperation Council (GCC) Countries |
| 14.5.2. South Africa |
| 14.5.3. Rest of MEA |
| 14.6. MEA Cytotoxic Drug Market - Opportunity Analysis Index, By Product Type, By Route of Administration, By Application, By End User, and Country, 2024 - 2030 |
| 14.7. MEA Cytotoxic Drug Market Dynamics Trends |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, Key Product Types, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. Pfizer Inc. |
| 15.2.2. AbbVie Inc. |
| 15.2.3. Johnson & Johnson |
| 15.2.4. GlaxoSmithKline PLC |
| 15.2.5. F. Hoffmann-La Roche AG |
| 15.2.6. Bristol-Myers Squibb |
| 15.2.7. Merck & Co. Inc. |
| 15.2.8. Sanofi |
| 15.2.9. Novartis AG |
| 15.2.10. Eli Lilly and Company |
| 15.2.11. Amgen |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.